|Day's Range||0.1000 - 0.1000|
Acceleron Pharma's (XLRN) pipeline candidate, ACE-083, fails to translate muscle volume growth into improvements in functional tests in FSHD patients. Acceleron discontinues development.
Acorda Therapeutics, Inc. (ACOR) today announced that it will present data at the International Congress of Parkinson’s Disease and Movement Disorders, taking place September 22-26, 2019 in Nice, France. Acorda and other industry sponsors are members of The Michael J. Fox Foundation Industry Advisory Board and contributed to the design of and provided funding for the “Financial and Social Impact of Parkinson’s Disease Survey.” Results of the survey were also presented at the 5th World Parkinson Congress in June 2019. Acorda will also host a Corporate Therapeutics Symposium, “Rethinking the Approach to Managing OFF Periods,” on Tuesday, September 24 from 12:45 PM to 1:45 PM CEST in the Nice Acropolis Convention Centre.
The FDA grants orphan drug status to Akari's (AKTX) nomacopan for the treatment of bullous pemphigoid, a severe blistering skin condition.
Adaptimmune Therapeutics (ADAP) gets Orphan Drug Designation for SPEAR T-cells targeting MAGE-A4 (ADP-A2M4 program) for the treatment of soft tissue sarcomas.
Horizon (HZNP) announces the FDA has accepted the Biologics License Application (BLA) for teprotumumab, for the treatment of active thyroid eye disease, and granted it Priority Review designation.
Some stocks are best avoided. We really hate to see fellow investors lose their hard-earned money. Imagine if you held...
Acorda's (ACOR) lead MS drug Ampyra is hit by generic rivalry in the United States, which is hurting the company's top line. Parkinson's disease drug Inbrija can be an ideal replacement.
Synlogic (SYBX) discontinues the development of its early-stage pipeline candidate, SYNB1020, for the treatment of hyperammonemia, following disappointing study results.
Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGVHD).
Regeneron's (REGN) study on four investigational therapies for Ebola virus infection is stopped early as its therapy, REGN-EB3, was superior to Mapp Biopharmaceutical Inc.'s ZMapp in preventing death.
Epizyme (EPZM) reports wider-than-expected loss in the second quarter of 2019 and the FDA accepts the NDA for its lead pipeline candidate, tazemetostat.